UY34796A - Formulacion de tobramicina - Google Patents

Formulacion de tobramicina

Info

Publication number
UY34796A
UY34796A UY0001034796A UY34796A UY34796A UY 34796 A UY34796 A UY 34796A UY 0001034796 A UY0001034796 A UY 0001034796A UY 34796 A UY34796 A UY 34796A UY 34796 A UY34796 A UY 34796A
Authority
UY
Uruguay
Prior art keywords
formulation
tobramycin
tobramycin formulation
mosmol
osmolarity
Prior art date
Application number
UY0001034796A
Other languages
English (en)
Inventor
Hawkins Kevin
Higahm David
Original Assignee
Norton Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norton Healthcare Ltd filed Critical Norton Healthcare Ltd
Publication of UY34796A publication Critical patent/UY34796A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una formulación de solución farmacéutica que comprende tobramicina, agua, cloruro de sodio y citrato de sodio, en donde la formulación tiene un pH de 4,5-7,0 y una osmolaridad de 135-200 mOsmol/Kg.
UY0001034796A 2012-05-09 2013-05-08 Formulacion de tobramicina UY34796A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644700P 2012-05-09 2012-05-09
GBGB1208080.0A GB201208080D0 (en) 2012-05-09 2012-05-09 Tobramycin formulation

Publications (1)

Publication Number Publication Date
UY34796A true UY34796A (es) 2014-11-28

Family

ID=46396721

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034796A UY34796A (es) 2012-05-09 2013-05-08 Formulacion de tobramicina

Country Status (10)

Country Link
US (1) US9012416B2 (es)
EP (1) EP2662093B1 (es)
BR (1) BR112014027708A2 (es)
DK (1) DK2662093T3 (es)
GB (1) GB201208080D0 (es)
PL (1) PL2662093T3 (es)
PT (1) PT2662093E (es)
TW (1) TWI488656B (es)
UY (1) UY34796A (es)
WO (1) WO2013167233A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2565941A (en) * 2018-11-27 2019-02-27 Norton Healthcare Ltd A process for preparing a formulation
CN113018443B (zh) * 2019-12-27 2022-09-13 海南斯达制药有限公司 治疗呼吸系统疾病的药物组合物及其制备方法
CN113952320B (zh) * 2021-09-18 2022-03-18 健康元药业集团股份有限公司 一种包含妥布霉素吸入溶液的药物组件及其用途
CN114796107B (zh) * 2022-05-09 2024-01-09 西藏邦臣药业集团有限公司 含二磷酸烟苷的硫酸妥布霉素注射液及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
PT1320355E (pt) 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
ES2222294T3 (es) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
DK1673074T3 (da) 2003-10-15 2007-05-07 Pari Gmbh Flydende præparat, indeholdende tobramycin
JP4674162B2 (ja) 2003-11-14 2011-04-20 千寿製薬株式会社 アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤
CN101080230A (zh) 2005-05-13 2007-11-28 维纳斯药业有限公司 包括囊性纤维化的严重感染的治疗和控制
CN100341899C (zh) 2005-11-01 2007-10-10 中国药科大学 新的壳聚糖衍生物、其制法及其用于制备眼科制剂的用途
CN101129381B (zh) 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN1927201B (zh) 2006-08-25 2011-06-01 天津和美生物技术有限公司 含哌拉西林的抗生素复方
WO2008130211A1 (es) 2007-04-20 2008-10-30 Serral, S.A. De C.V. Solución dinámica, estequiométrica de soporte y de equilibrio inducido
US7795316B1 (en) * 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
KR20130094280A (ko) 2010-06-23 2013-08-23 알콘 리서치, 리미티드 토브라마이신과 덱사메타손을 함유하는 국소 안과 현탁액

Also Published As

Publication number Publication date
EP2662093A1 (en) 2013-11-13
WO2013167233A1 (en) 2013-11-14
EP2662093B1 (en) 2015-01-14
TW201350138A (zh) 2013-12-16
BR112014027708A2 (pt) 2017-07-18
PT2662093E (pt) 2015-02-17
US9012416B2 (en) 2015-04-21
PL2662093T3 (pl) 2015-06-30
GB201208080D0 (en) 2012-06-20
TWI488656B (zh) 2015-06-21
DK2662093T3 (en) 2015-02-16
US20130303475A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
CL2014002258A1 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.
AR098168A1 (es) Formulación estable de insulina glulisina
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
AR081983A1 (es) Articulo de dosis unitaria soluble que comprende un polimero cationico
MX2017008277A (es) Solucion oftalmica acuosa.
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
AR089203A1 (es) Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina y metodo de tratamiento
AR104591A1 (es) Piroglutamato de vortioxetina
CL2014002780A1 (es) Mezcla que mejora crecimiento de plantas que comprende las etapas de mezclar una solucion acuosa que incluye trehalosa o trehalosa-6-fosfato.
ECSP15010550A (es) Preparación farmacéutica sólida que contiene levotiroxina
UY34796A (es) Formulacion de tobramicina
AR089486A1 (es) PREPARACION FARMACEUTICA QUE COMPRENDE b-CICLODEXTRINA SUSTITUIDA
CL2017000244A1 (es) Formulaciones de compuestos biológicos para instilación intravesical.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
AR098513A1 (es) Dispensador de dentífrico y sistema del cuidado oral que comprende el mismo
BR112013027391A2 (pt) formulação farmacêutica, frasco e kit
ES2530751T3 (es) Formulación de tobramicina
FR3019047B1 (fr) Diffuseur d'agent parfumant et/ou assainissant active par retournement.
BR112015026516A2 (pt) agentes antibacterianos de fenicol inovadores

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528